Physician profile
Robert P Cusick
NPI 1184606790
$27,628.52
in general payments reported to CMS, 2019-2025
14 companies · $2,035 in 2025
The $2,035 reported for 2025 was more than what a typical Adult Reconstructive Orthopaedic Surgery provider received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $762 · 2021: $305 · 2022: $161 · 2023: $570 · 2024: $1,358 · 2025: $2,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,042 · Food and Beverage: $1,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,041.60 |
| Food and Beverage | $1,921.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Midwest Surgical Alliance, LLC | $22,000.00 | 2019 | |
| Stryker Corporation | $4,243.98 | 2019-2025 | Mako, Aequalis Perform, Triathlon |
| Encore Medical, LP | $912.94 | 2020-2025 | Djo Surgical |
| Pacira Therapeutics, INC. | $79.26 | 2019 | |
| Depuy Synthes Sales INC. | $78.89 | 2021-2023 | Tfn-Advance, Kincise |
| Ethicon US, LLC | $74.91 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $53.66 | 2021-2025 | Euflexxa |
| Orthofix Medical, INC. | $47.88 | 2022-2023 | Physio-Stim |
| Sanofi-Aventis U.S. LLC | $36.60 | 2019 | |
| Bioventus LLC | $27.74 | 2025 | Xcell |
| Merck Sharp & Dohme LLC | $22.49 | 2025 | Bridion |
| Pacira Pharmaceuticals Incorporated | $18.21 | 2025 | Exparel |
| Amgen INC. | $17.43 | 2022 | |
| Endo Pharmaceuticals INC. | $14.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$157,940.85 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cusick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.